'Charlemagne' Chessman pawn (actually 11th century)
seen from United States

seen from United States

seen from Thailand

seen from Türkiye

seen from United Kingdom

seen from United Kingdom

seen from United Kingdom

seen from Canada
seen from Macao SAR China
seen from United States
seen from China
seen from Brazil
seen from Japan
seen from Netherlands

seen from United States
seen from China
seen from United States
seen from Brazil
seen from Germany
seen from China
'Charlemagne' Chessman pawn (actually 11th century)
St. John the Evangelist, Hans Memling, 1470s, for Sir John Donne (source)
Major Pharmaceutical Preparations Company's Deficit Widens in Fiscal First Quarter of 2024 https://csimarket.com/stocks/news.php?code=ARWR&date=2024-02-06232635&utm_source=dlvr.it&utm_medium=tumblr
Arrowhead Pharmaceuticals (ARWR): Q4 2019 Earnings Snapshot
Arrowhead Pharmaceuticals (ARWR): Q4 2019 Earnings Snapshot
— Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of 65 cents per share a year ago.
— For the full year, revenue rose to $168.7 million, vs. $16.1 million last year.
— Began dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study…
View On WordPress
Trading At Over Twice The 52 Week Low, Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR) Close At $12.52
Trading At Over Twice The 52 Week Low, Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR) Close At $12.52
Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR)
November 15th, 2018 Amidst falling markets Arrowhead Pharmaceuticals Inc finished up $0.46 Thursday, a 3.81% increase, closing at $12.52. The stock continues to trade well at 316% of its 52 week low of $3.01. While it is positive news the stock ended higher, the trading volumes were only 10% of normal which could be an indication of investor…
View On WordPress
Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR) Analysts Are Cautiously Optimistic
Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR) Analysts Are Cautiously Optimistic
Arrowhead Pharmaceuticals Inc (Nasdaq:ARWR)
October 6th, 2018
Amidst falling markets Arrowhead Pharmaceuticals Inc finished Thursday’s trading session down 3.85%, a $0.59 decrease to close on $14.74. While the stock did drop today, remember that it is still trading at 390% of its 52 week low of $3.01. Arrowhead Pharmaceuticals Inc swung 11.67% between high and low. (more…)
View On WordPress
$ARWR 2018-08-19 : Transcripts- Edited Transcript of ARWR earnings conference call
$ARWR 2018-08-19 : Transcripts- Edited Transcript of ARWR earnings conference call
[s2If !current_user_can(access_s2member_level0)] Please login to read the transcript. [lwa] [/s2If][s2If current_user_can(access_s2member_level0)]”
Q3 2018 Arrowhead Pharmaceuticals Inc Earnings Call
PASADENA Aug 20, 2018 (Thomson StreetEvents) — Edited Transcript of Arrowhead Pharmaceuticals Inc earnings conference call or presentation Tuesday, August 7, 2018 at 8:30:00pm GMT
TEXT version…
View On WordPress
$ARWR 2018-08-17 : Transcripts- Edited Transcript of ARWR earnings conference call
$ARWR 2018-08-17 : Transcripts- Edited Transcript of ARWR earnings conference call
[s2If !current_user_can(access_s2member_level0)] Please login to read the transcript. [lwa] [/s2If][s2If current_user_can(access_s2member_level0)]”
Q3 2018 Arrowhead Pharmaceuticals Inc Earnings Call
PASADENA Aug 18, 2018 (Thomson StreetEvents) — Edited Transcript of Arrowhead Pharmaceuticals Inc earnings conference call or presentation Tuesday, August 7, 2018 at 8:30:00pm GMT
TEXT version…
View On WordPress